China Dermatology Drugs Market Analysis Report 2022 to 2030

China Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the China Dermatology drugs market will reach a value of $3.46 Bn from $1.37 Bn in 2022, growing at a CAGR of 12.3% during 2022-2030. The dermatology drug market in China is dominated by a few large pharmaceutical companies such as Johnson and Johnson Shanghai, China Resources Pharmaceutical Group and Chongqing Huapont Pharm. The dermatology drug market in China is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel. The major factors affecting the China dermatology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of China.

ID: IN10CNPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Vishwa Modhia

Buy Now

China Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the China Dermatology drugs market will reach a value of $3.46 Bn from $1.37 Bn in 2022, growing at a CAGR of 12.3% during 2022-2030. In Chinese general hospitals, patients with skin conditions typically make up 10% of the outpatient population and rank among the most prevalent patients in primary care. The dermatological drugs market is expected to generate $1.93 Bn in revenue by 2023. The Chinese economy continues to expand at a high rate, which has been fuelled by long-term increases in industrial output, imports and exports, consumer spending, and capital investment.

Traditional Chinese medicine (TCM) is a complementary form of treatment that can be given orally, topically, or intravenously. It has gained popularity as a method of treating dermatologic diseases among some patient populations. It is now advantageous for dermatologists in the West to become familiar with this technique.

china dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

The market is also anticipated to benefit from the increase in domestic and international business alliances and partnerships. Additional elements that are anticipated to support the market's growth include the Chinese government's focus on improving its healthcare system and the growing accessibility of FDA-approved medications for the treatment of skin conditions.

Market Restraints

The number of dermatologists in China is estimated to be 30,000, which represents 0.0016% of the country's total population with skin conditions. A total of 17,100 dermatologists work in hospitals, most of which are found in economically developed regions. In contrast, some local hospitals in isolated areas do not offer skin disease treatment.

Competitive Landscape

Key Players

Johnson and Johnson Shanghai (CHN)
China Resources Pharmaceutical Group (CHN)
Chongqing Huapont Pharm Co. (CHN)
Bright Future Pharmaceutical Laboratories (CHN)
Xiuzheng Pharmaceutical Group (CHN)
China National Pharmaceutical Group (CHN)
Harbin Letai (CHN)
Hebei Xinglong Xili Pharmaceutical Industry (CHN)
Bayer Healthcare
Glaxosmithkline

Notable Recent Deals

July 2022: In Mainland China, Taiwan, Hong Kong, and Macao (collectively referred to as "Greater China"), Cosmo Pharmaceuticals N.V. and 3SBio announced the signing of a License Agreement for Winlevi (clascoterone) cream 1%. Sun Pharma's Winlevi, which was introduced in the US in November 2021, is currently the most frequently prescribed branded topical acne medication in the country.

Healthcare Policies and Reimbursement Scenario

Drugs and medical devices are overseen by the former China Food and Drug Administration (CFDA) now the National Medical Products Administration (NMPA), which reports to the State Administration of Market Regulation (SAMR). NMPA is responsible for conducting drug registration and approvals, provides guidance to provincial authorities, and works with provincial-level investigators to assign inspections of clinical trial facilities and international inspections.

The reimbursement policy for dermatology drugs in China is determined by the National Reimbursement Drug List (NRDL). Drugs included on the NRDL are eligible for reimbursement by the government, and the prices for these drugs are also regulated by the government.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.